Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nautilus Biotechnology, Inc. (NAUT : NSDQ)

• Company Description    Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $0.72 Daily Weekly Monthly 20 Day Moving Average: 238,015 shares Shares Outstanding: 126.31 (millions) Market Capitalization: $91.03 (millions) Beta: 1.42 52 Week High: $3.09 52 Week Low: $0.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.15% -1.91% 12 Week 1.79% -7.54% Year To Date -57.10% -62.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2701 EASTLAKE AVE EAST - SEATTLE,WA 98102 USA ph: 206-333-2001 fax: - investorrelations@nautilus.bio http://www.nautilus.bio

• General Corporate Information    Officers Sujal Patel - Chief Executive Officer; President and Director Anna Mowry - Chief Financial Officer Michael Altman - Director Melissa Epperly - Director Parag Mallick - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 63909J108 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 126.31 Most Recent Split Date: (:1) Beta: 1.42 Market Capitalization: $91.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 14.29% vs. Previous Quarter: 7.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -32.53 03/31/25 - -31.87 12/31/24 - -30.88 ROA 06/30/25 - -27.85 03/31/25 - -27.39 12/31/24 - -26.61 Current Ratio 06/30/25 - 18.52 03/31/25 - 17.36 12/31/24 - 17.40 Quick Ratio 06/30/25 - 18.52 03/31/25 - 17.36 12/31/24 - 17.40 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 1.43 03/31/25 - 1.54 12/31/24 - 1.66 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©